Replies to post #145521 on Biotech Values

[DewDiligence]

ENDP buys Par Pharma, a generic-drug company that went private in 2012, for $8.1B in cash and stock:

http://finance.yahoo.com/news/endo-acquire-par-pharmaceutical-strategically-103000230.html

TPG, a leading private-equity firm, paid $1.9B for Par in Jul 2012 (#msg-77533202), and thereby quadrupled their investment in less than three years! Such returns are possible thanks to a bull market the availability of cheap debt.